**Supplementary Table.** Adjusted 5-years risk of non-fatal cardiovascular events or hospitalizations for heart failure attributable to high dp-ucMGP or high sclerostin.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | ***Model A*** | |  | ***Model B*** | |
| HRR (95%CI´s) | *p-value* | HRR (95%CI´s) | *p-value* |
| ***Non-fatal cardiovascular events:***  age decade  male gender  coronary revascularization  current smoking  body mass index ≥30 kg/m2  raised blood pressure†  LDL ≥1.8 mmol/L  poor glycemic control**‡**  estimated glomerular filtration ≤60 mL/min  brain natriuretic peptide ≥100 ng/mL  beta-blockers  RAAS blockers  statins  antidiabetics  dp-ucMGP ≥884 pmol/L  sclerostin ≥589 ng/L | 0.78 (0.61-1.00)  0.55 (0.36-0.86)  1.46 (0.46-4.65)  1.68 (1.06-2.67)  1.00 (0.67-1.50)  1.26 (0.84-1.89)  1.08 (0.64-1.80)  1.12 (0.72-1.74)  0.85 (0.54-1.35)  1.53 (1.01-2.34)  0.69 (0.40-1.20)  1.32 (0.80-2.18)  0.89 (0.48-1.64)  0.97 (0.59-1.60)  1.32 (0.81-2.16) | 0.048  0.009  0.518  0.027  0.999  0.269  0.779  0.619  0.493  0.046  0.188  0.746  0.700  0.915  0.267 |  | 0.77 (0.60-0.99)  0.59 (0.37-0.93)  1.46 (0.46-4.63)  1.63 (1.04-2.57)  0.99 (0.66-1.48)  1.33 (0.89-1.99)  1.10 (0.66-1.84)  1.18 (0.76-1.82)  0.91 (0.58-1.42)  1.62 (1.07-2.45)  0.72 (0.42-1.24)  1.34 (0.82-2.21)  0.89 (0.48-1.65)  0.97 (0.60-1.59)  0.81 (0.48-1.36) | 0.037  0.024  0.522  0.034  0.942  0.169  0.719  0.469  0.671  0.022  0.238  0.246  0.716  0.914  0.424 |
| ***Hospitalization for heart failure :***  age decade  male gender  coronary revascularization†  current smoking  body mass index ≥30 kg/m2  raised blood pressure†  LDL ≥1.8 mmol/L  poor glycemic control†  estimated glomerular filtration ≤60 mL/min  brain natriuretic peptide ≥100 ng/mL  beta-blockers  RAAS blockers  statins  antidiabetics  dp-ucMGP ≥884 pmol/L  sclerostin ≥589 ng/L | 1.40 (0.99-1.97)  1.12 (0.65-1.95)  0.43 (0.20-0.92)  1.34 (0.65-2.79)  0.80 (0.37-1.70)  1.71 (1.07-2.74)  0.61 (0.37-1.01)  1.18 (0.70-1.98)  1.58 (0.94-2.65)  4.22 (2.41-7.39)  0.87 (0.45-1.69)  1.58 (0.82-3.04)  0.73 (0.36-1.45)  1.13(0.66-1.94)  1.28 (0.77-2.13) | 0.056  0.684  0.029  0.432  0.556  0.026  0.054  0.529  0.087  <0.0001  0.686  0.174  0.361  0.658  0.347 |  | 1.40 (1.00-1.98)  0.90 (0.50-1.64)  0.47 (0.22-1.01)  0.92 (0.45-1.91)  1.61 (1.01-2.56)  0.73 (0.46-1.16)  0.61 (0.37-0.99)  1.11 (0.66-1.87)  1.54 (0.94-2.53)  4.13 (2.40-7.08)  0.80 (0.42-1.50)  1.58 (0.82-3.04)  0.73 (0.37-1.44)  1.22 (0.71-2.09)  1.74 (1.05-2.88) | 0.053  0.735  0.054  0.832  0.046  0.188  0.046  0.690  0.087  <0.0001  0.482  0.171  0.360  0.470  0.031 |

†systolic ≥140 and/or diastolic blood pressure ≥90 mmHg; **‡**fasting glycemia ≥7 mmol/L and/or HBA1c ≥48 mmol/mol;

model A included also treatment with warfarin and both model survey (i.e. EUROASPIRE III or IV);